Lupin Limited, a global pharmaceutical leader, has announced a new partnership with Honeywell to use Honeywell’s Solstice® Air propellant in next-generation inhalers. This collaboration aims to improve treatment for patients with asthma and chronic obstructive pulmonary disease (COPD). At the same time, it seeks to reduce the environmental impact of inhaler technology.
Solstice Air is a modern, non-flammable propellant that serves as an alternative to traditional hydrofluorocarbon (HFC) propellants. It can lower greenhouse gas emissions by up to 99.9%. This initiative supports Lupin’s goal to cut the carbon footprint of its respiratory medicines while maintaining effective patient care.
Lupin intends to be the first pharmaceutical company in India to use Honeywell’s Solstice Air propellant on a large scale in pressurized metered-dose inhalers (pMDIs). By adopting this new technology, Lupin is making a significant move towards reducing carbon emissions and promoting sustainable healthcare.
Vinita Gupta, CEO of Lupin, said, “Our partnership with Honeywell shows our commitment to delivering high-quality treatments and creating a healthier, more sustainable future for our patients and communities worldwide. Using Solstice Air helps us improve care while lowering the environmental impact of our respiratory products.”
Ashish Modi, President of Honeywell India, commented, “Solstice Air is key to making sure Lupin’s inhalers provide safe and effective treatment. It also uses the latest technology to cut harmful greenhouse gas emissions. Honeywell is dedicated to advancing innovations that boost healthcare and support environmentally responsible practices.”
The two companies are still finalizing the details of their partnership.
Honeywell is a global technology leader with operations in aerospace, industrial automation, energy, and sustainability. The company focuses on solving complex challenges with innovative solutions that improve safety, security, and sustainability worldwide.
